CUMBERLAND, R.I.--(BUSINESS WIRE)--Onset Therapeutics, a specialty pharmaceutical company focused in dermatology, today announced the FDA approval and commercial launch of HYLATOPIC™ Emollient Foam, a unique, non-steroidal prescription product indicated to manage and relieve the burning, itching and pain experienced with various types of dermatoses, including atopic dermatitis, allergic contact dermatitis and radiation dermatitis.
